- Sputnik International, 1920
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Russia's Gamaleya Institute to Test Antibody-Based COVID-19 Drug on People Late in 2021

© Sputnik / Evgeniy Odinokov / Go to the mediabankEvaluation of Sputnik V Vaccine Effectiveness in the Gemotest Laboratory in Moscow, Russia
Evaluation of Sputnik V Vaccine Effectiveness in the Gemotest Laboratory in Moscow, Russia - Sputnik International, 1920, 02.04.2021
MOSCOW (Sputnik) - Russia's Gamaleya research institute will start clinical trials of its antibody-based drug against the coronavirus on people at the end of the year, the medication should help significantly reduce mortality from COVID-19, institute chief Alexander Gintsburg said in an interview with Sputnik.

"I hope that at the end of this year we will proceed to the first phase of the clinical trials, I mean it will be tested on people. We will certainly check safety first. The drug will be administered in hospitals, to patients who were admitted with this infection," Gintsburg said.

Baby  - Sputnik International, 1920, 02.04.2021
Russia's Gamaleya Chief Confirms COVID-19 Antibodies Transmit From Mothers to Babies
The director of the Gamaleya institute, which developed the Sputnik V vaccine, clarified that the drug would help in cases that currently result in patients' death, which means the death rate should decrease sharply.

"By the middle of 2022, we will have completed the second and the third stages of the clinical trials," Gintsburg went on to say.

Developers will try to make the drug affordable, Gintsburg pledged.

To participate in the discussion
log in or register
Заголовок открываемого материала